Stable Renal Function and Benign Course in Azotemic Diabetics Treated with Erythropoietin for One Year1

2015 ◽  
pp. 182-191 ◽  
Author(s):  
Clinton D. Brown ◽  
Eli A. Friedman
Keyword(s):  
Renal Function ◽  
Stable Renal Function ◽  
Benign Course

scholarly journals SP723EXPRESSION OF CXCR3 MONOCYTES INCREASES SIGNIFICANTLY IN THE GRAFT BLOOD COMPARED TO PERIPHERAL BLOOD IN PATIENTS WITH STABLE RENAL FUNCTION

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii382-iii382
Author(s):  
Abelardo Caballero ◽  
Pedro Ruiz-Esteban ◽  
Eulalia Palma ◽  
Alberto Torio ◽  
Mercedes Cabello ◽  
...  
Keyword(s):  
Renal Function ◽  
Peripheral Blood ◽  
Stable Renal Function

Clinic-Pathologic Features and Renal Outcome of Fabry Disease: Data from a Chinese Cohort

2018 ◽  
Vol 48 (2) ◽  
pp. 137-146
Author(s):  
Dan Zhang ◽  
Jiong Zhang ◽  
Shaoshan Liang ◽  
Jinquan Wang ◽  
Zhihong Liu
Keyword(s):  
Renal Function ◽  
Survival Rate ◽  
Fabry Disease ◽  
Left Ventricular ◽  
Renal Outcome ◽  
Characteristic Analysis ◽  
Renal Function Deterioration ◽  
Renal Prognosis ◽  
Stable Renal Function ◽  
Fabry Nephropathy

Background: Fabry disease (FD) with life-threatening complications occurs as a result of organ damage in kidneys, heart, and brain. Only a few studies, especially from Asia, report their long-term outcome. Methods: In this monocentric study, patients with Fabry nephropathy confirmed by renal biopsy were clinically investigated in a comprehensive manner. The clinic-pathological features, progression, and risk factors for the outcome were analyzed. Results: Thirty-one patients were recruited, after median 62 months (range 8–156 months) follow-up, 23 of them had stable renal function while 8 underwent renal function deterioration. Frequent presenting symptoms included acroparesthesia (58.1%), edema (51.6%), hypo- or anhidrosis (38.7%), and angiokeratoma (32.3%). Left ventricular hypertrophy was present in 62.5% patients with renal function deterioration and 17.4% patients with stable renal function (p = 0.03). The renal cumulative survival rate of all patients was 64.5% in 10 years. Mainz Severity Score Index (MSSI) and segmental sclerosis are independent predictive factors for a more rapid progression of Fabry nephropathy. The receiver operating characteristic analysis demonstrated that the area under the curve for the prediction of renal function progression on the basis of MSSI and segmental sclerosis levels in patients with FD was 0.845 and 0.780, respectively. MSSI score ≥18 or segmental sclerosis ≥3.9% in patients with FD positively correlated with poor renal prognosis. Conclusions: FD’s clinical manifestations are heterogeneous and nonspecific. The ­10-year cumulative renal survival rate was low in Chinese patients. MSSI score and segmental sclerosis levels predict the renal prognosis of patients with FD sensitively.

Measuring renal function in old age

1999 ◽  
Vol 9 (3) ◽  
pp. 215-219 ◽  
Author(s):  
JM Coyle ◽  
BK Bhowmick ◽  
RJ Meara
Keyword(s):  
Renal Function ◽  
Glomerular Filtration Rate ◽  
Old Age ◽  
Renal Mass ◽  
Filtration Rate ◽  
Elderly Subjects ◽  
Cross Sectional ◽  
Functional Changes ◽  
Progressive Loss ◽  
Stable Renal Function

The accurate measurement of renal function in elderly subjects is often required, due to structural and functional changes resulting from age and diseases affecting the kidney. Structurally, with age there is progressive loss of renal mass, particularly in the cortex, leading to a decreased number of glomeruli and an increase in the proportion of sclerotic glomeruli. A decline in the glomerular filtration rate (GFR) has been observed in both cross-sectional and longitudinal studies. However, it has also been noted that about one third of subjects have stable renal function, implying that this decline is not universal, and may reflect the effects of age-associated diseases.

Update On Phase 2 Clinical Trial To Induce Tolerance In Mismatched Living Donor Renal Transplant Recipients

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4622-4622
Author(s):  
Joseph Leventhal ◽  
Michael Abecassis ◽  
Joshua Miller ◽  
Lorenzo Gallon ◽  
David J Tollerud ◽  
...  
Keyword(s):  
Renal Function ◽  
Living Donor ◽  
Graft Loss ◽  
Renal Transplant Recipients ◽  
Phase 2 ◽  
Peripheral Blood Mononuclear ◽  
Protocol Biopsy ◽  
Engraftment Syndrome ◽  
Stable Renal Function ◽  
Equity Ownership

Nineteen subjects have been enrolled in a phase 2 protocol (FDA IDE 13947) to induce donor-specific tolerance in HLA-mismatched related and unrelated recipients of living donor renal allografts (KTx). The protocol is based upon tolerogenic CD8+/TCR- facilitating cells (FC) and nonmyeloablative conditioning. Recipients are conditioned with fludarabine (30 mg/kg/dose, days -5, -4, -3), cyclophosphamide (50 mg/kg/dose, day -3 and +3), 200 cGy TBI (day -1) followed by KTx (day 0). A G-CSF mobilized peripheral blood mononuclear cell product is apheresed from the donor > 2 weeks prior to the KTx, processed to remove GVHD-producing cells yet retain CD34+ cells and FC (FCRx), and cryopreserved until infusion on day +1 post-KTx. Subjects ranged in age from 18 to 65 years. All were HLA-disparate from their donors, ranging from 5 of 6 matched related to 0 of 6 unrelated. 18 of 19 subjects exhibited engraftment at 1 month; one highly sensitized subject (PRA > 50%) did not engraft. Subjects were discharged on post-operative day 2 and managed as outpatients. Mycophenolate mofetil and tacrolimus-based immunosuppression were administered for 6 months. At 6 months the MMF was discontinued if the protocol biopsy was normal and stable renal function present. Tacrolimus was weaned at month 9 (trough levels 3-6) and discontinued at 1 year if chimerism, normal renal function, and normal kidney biopsy were noted. No subjects have experienced GVHD or engraftment syndrome. Two early subjects who received a suboptimal cell dose and one other highly sensitized subject were only transiently chimeric (< 6 months); all transiently chimeric subjects resumed endogenous hematopoiesis and are maintained on low-dose tacrolimus monotherapy with stable renal function. The protocol was subsequently modified to exclude subjects with a PRA > 20%. One chimeric subject developed viral sepsis at month 3, thrombosed his kidney, and was successfully re-transplanted off study. A second subject developed CNI-induced hemolytic uremic syndrome (HUS) which resulted in graft loss. He is currently off all immunosuppression and his HUS has resolved. The remaining subjects are either off all immunosuppression (n = 9; 1 to 36 months) or are in the process of tapering. None of the chimeric subjects have developed rejection on protocol biopsy while 3 of the 5 who were not durably chimeric had Banff 1A rejection on protocol biopsy. Recurrence of autoimmune disease has occurred in 2 of 4 non-chimeric subjects, but not in any of the durable chimeric subjects. In summary, high levels of durable chimerism and tolerance without GVHD have been achieved in mismatched related and unrelated recipients of living KTx. Disclosures: Tollerud: Regenerex, LLC: Equity Ownership. Ildstad:Regenerex, LLC: Equity Ownership.

Elective conversion from cyclosporine to azathioprine in recipients with stable renal function 6 months after kidney transplantation

1985 ◽  
Vol 14 (3) ◽  
pp. 314-323 ◽  
Author(s):  
J.Richard Thistlethwaite ◽  
Brian W. Haag ◽  
Kenneth W. Jones ◽  
Joan K. Stuart ◽  
Frank P. Stuart
Keyword(s):  
Renal Function ◽  
Kidney Transplantation ◽  
Stable Renal Function

Reproducibility of the measurements of creatinine clearance in patients with a stable renal function

2004 ◽  
Vol 36 (1) ◽  
pp. 109-112
Author(s):  
Katarzyna Wieczorowska-Tobis ◽  
Przemyslaw Guzik ◽  
Zofia Niemir ◽  
Andrzej Breborowicz ◽  
Dimitrios G. Oreopoulos
Keyword(s):  
Renal Function ◽  
Creatinine Clearance ◽  
Stable Renal Function

scholarly journals Laparoscopic Nephrectomy,Ex VivoPartial Nephrectomy, and Autotransplantation for the Treatment of Complex Renal Masses

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Jasmir Gopal Nayak ◽  
Joshua Koulack ◽  
Thomas Brian McGregor
Keyword(s):  
Renal Function ◽  
Partial Nephrectomy ◽  
Ex Vivo ◽  
Laparoscopic Nephrectomy ◽  
Cell Renal Cell Carcinoma ◽  
Renal Masses ◽  
Local Experience ◽  
Nephron Sparing ◽  
Stable Renal Function ◽  
Clinical Dilemma

In the contemporary era of minimally invasive surgery, very few T1/T2 renal lesions are not amenable to nephron-sparing surgery. However, centrally located lesions continue to pose a clinical dilemma. We sought to describe our local experience with three cases of laparoscopic nephrectomy,ex vivopartial nephrectomy, and autotransplantation. Laparoscopic donor nephrectomy was performed followed by immediate renal cooling and perfusion with isotonic solution. Back-table partial nephrectomy, renorrhaphy, and autotransplantation were then performed. Mean warm ischemia (WIT) and cold ischemic times (CIT) were 2 and 39 minutes, respectively. Average blood loss was 267 mL. All patients preserved their renal function postoperatively. Final pathology confirmed pT1, clear cell renal cell carcinoma with negative margins in all. All are disease free at up to 39 months follow-up with stable renal function. In conclusion, the described approach remains a viable option for the treatment of complex renal masses preserving oncological control and renal function.

Sign in / Sign up

Export Citation Format

Share Document